Doximity, Inc. (DOCS) Stock Analysis
Falling Knife setup · Temp Headwind edge
Healthcare · Health Information Services
Sell if holding. At $19.17, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.1): -0.5; Weak growth.
Doximity is the leading digital platform for U.S. medical professionals, with 2M+ registered members including 80%+ of U.S. physicians, offering Marketing, Hiring, and Workflow solutions to pharmaceutical and health system customers. Revenue is subscription-based with no single... Read more
Sell if holding. At $19.17, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.1): -0.5; Weak growth. Chart setup: Death cross, below all MAs, RSI 31, MACD bearish. Score 5.4/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Doximity, Inc.
Latest news
- Doximity Stock Dives On Q4 Earnings, Weak Outlook - Benzinga — Benzinga negative
- Doximity (NYSE:DOCS) Posts Q1 CY2026 Sales In Line With Estimates But Stock Drops 11.1% - Yahoo Finance — Yahoo Finance negative
- Doximity (DOCS): Buy, Sell, or Hold Post Q4 Earnings? - StockStory — StockStory neutral
- Doximity (DOCS) Q1 Earnings: What To Expect - StockStory — StockStory neutral
- Doximity (DOCS) Q1 Earnings: What To Expect - TradingView — TradingView neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-17Item 5.02HIGHCFO Anna Bryson resigned April 13, 2026 (had been on medical leave since Feb 5). Siddharth Sitaram (Chief Accounting Officer) continues as interim principal financial officer. Company expects update on CFO search at next earnings call. No permanent successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $19.17, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.1): -0.5; Weak growth. Chart setup: Death cross, below all MAs, RSI 31, MACD bearish. Prior stop was $17.91. Score 5.4/10, moderate confidence.
Take-profit target: $22.63 (+17.5% upside). Prior stop was $17.91. Stop-loss: $17.91.
Leverage penalty (D/E 1.1): -0.5; Weak growth; Negative momentum.
Doximity, Inc. trades at a P/E of 19.7 (forward 12.1). TrendMatrix value score: 7.6/10. Verdict: Sell.
30 analysts cover DOCS with a consensus score of 4.0/5. Average price target: $25.
What does Doximity, Inc. do?Doximity is the leading digital platform for U.S. medical professionals, with 2M+ registered members including 80%+ of...
Doximity is the leading digital platform for U.S. medical professionals, with 2M+ registered members including 80%+ of U.S. physicians, offering Marketing, Hiring, and Workflow solutions to pharmaceutical and health system customers. Revenue is subscription-based with no single customer exceeding 10% of total, though concentrated within a small number of key customers and agencies.